PEJMF (Peijia Medical) EBITDA per Share: $-0.03 (TTM As of Dec. 2025)


PEJMF Peijia Medical Ltd PEJMF
74 GF Score
Price $1.39
GF Value $2.57
! 4 Warning Signs
View Full Analysis

What is Peijia Medical EBITDA per Share?

Peijia Medical PEJMF 74 EBITDA per Share is $-0.03 as of Dec. 2025. GuruFocus rates PEJMF with a GF Score™ of 74/100 and a GF Value™ of $2.57. The stock has 4 warning signs investors should review. Among 695 Medical Devices & Instruments companies, Peijia Medical ranks better than 77.12% on this metric.

Peijia Medical's EBITDA per Share for the six months ended in Dec. 2025 was $-0.02. Its EBITDA per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.03.

During the past 3 years, the average EBITDA per Share Growth Rate was 30.10% per year. During the past 5 years, the average EBITDA per Share Growth Rate was 44.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for Peijia Medical's EBITDA per Share or its related term are showing as below:

PEJMF' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -91   Med: 30.1   Max: 52.4
Current: 30.1

During the past 8 years, the highest 3-Year average EBITDA per Share Growth Rate of Peijia Medical was 52.40% per year. The lowest was -91.00% per year. And the median was 30.10% per year.

PEJMF's 3-Year EBITDA Growth Rate is ranked better than
77.12% of 695 companies
in the Medical Devices & Instruments industry
Industry Median: 7.9 vs PEJMF: 30.10

Peijia Medical's EBITDA for the six months ended in Dec. 2025 was $-13.3 Mil.

During the past 3 years, the average EBITDA Growth Rate was 30.30% per year. During the past 5 years, the average EBITDA Growth Rate was 41.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 8 years, the highest 3-Year average EBITDA Growth Rate of Peijia Medical was 46.10% per year. The lowest was -96.30% per year. And the median was 30.30% per year.


Peijia Medical  (OTCPK:PEJMF) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


Peijia Medical EBITDA per Share Related Terms


Peijia Medical EBITDA per Share Historical Data

* Premium members only.

The historical data trend for Peijia Medical's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Peijia Medical EBITDA per Share Chart

Peijia Medical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA per Share
Get a 7-Day Free Trial -0.13 -0.08 -0.07 -0.03 -0.03

Peijia Medical Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBITDA per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.04 -0.01 -0.02 -0.01 -0.02
PEJMF
74GF Score
Peijia Medical Ltd PEJMF
EBITDA per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Peijia Medical EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Peijia Medical's EBITDA per Share for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA per Share(A: Dec. 2025 )
=EBITDA/Shares Outstanding (Diluted Average)
=-17.465/665.234
=-0.03

Peijia Medical's EBITDA per Share for the quarter that ended in Dec. 2025 is calculated as

EBITDA per Share(Q: Dec. 2025 )
=EBITDA/Shares Outstanding (Diluted Average)
=-13.334/664.477
=-0.02

EBITDA per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA per Share →
What does a EBITDA per Share of $-0.03 mean?
Peijia Medical (PEJMF) has a EBITDA per Share of $-0.03 as of Dec. 2025. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on Peijia Medical and its competitors. According to the industry distribution chart, Peijia Medical ranks #159 out of 695 companies in the Medical Devices & Instruments industry, placing it in the top 22.9%.
Is Peijia Medical's EBITDA per Share too high?
Peijia Medical's current EBITDA per Share is $-0.03. Based on the distribution chart, Peijia Medical ranks #159 out of 695 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Peijia Medical has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Peijia Medical's EBITDA per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Peijia Medical ranks #159 out of 695 companies for EBITDA per Share. This places Peijia Medical in the top 23% of its industry — outperforming the majority of peers. The industry median EBITDA per Share is 7.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA per Share for a Medical Devices & Instruments company?
The median EBITDA per Share among Medical Devices & Instruments companies is 7.90, based on 695 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA per Share significantly above this median, while those in the bottom quartile fall well below. However, EBITDA per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA per Share mean?
A high EBITDA per Share can signal that a stock is expensive relative to its fundamentals. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on Peijia Medical and its competitors. For the Medical Devices & Instruments industry, the median EBITDA per Share is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Peijia Medical's current EBITDA per Share is $-0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Peijia Medical stock overvalued right now?
Peijia Medical (PEJMF) has a current EBITDA per Share of $-0.03. The stock's GF Value™ is $2.57, compared to a current price of $1.39 — trading 46% below its estimated fair value. The current EBITDA per Share is $-0.03. Peijia Medical's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA per Share calculated?
EBITDA per Share is calculated from a company's financial statements. For Peijia Medical (PEJMF), the current EBITDA per Share is $-0.03 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Peijia Medical (PEJMF) Overvalued in 2026?

Based on GuruFocus' analysis, Peijia Medical stock appears to be undervalued. The current stock price of $1.39 is trading 46% below its estimated GF Value™ of $2.57.

Key valuation signals for PEJMF:

  • EBITDA per Share: $-0.03
  • GF Value™: $2.57 vs. price of $1.39 (46% below fair value)
  • GF Score™: 74/100 with 4 warning signs

No single metric tells the full story. See the PEJMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Peijia Medical Business Description

Other Exchanges 09996:Hong Kong4WO:Germany
Address No.18 Yangjiatian Road, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN
Peijia Medical Ltdis a provider of inventive medical products and solutions. It focuses on the high-growth interventional procedural medical device market in China. Its products and product candidates target large, fast-growing and under-penetrated markets with high entry barriers, including the transcatheter valve therapeutic medical device market and the neurointerventional procedural medical device market. The Company's product pipeline consists of transcatheter valve therapeutic and neurointerventional products and product candidates spanning three key business segments: Transcatheter Valve Therapeutic Business, Future Technology Business and Neurointerventional Business.
74GF Score

Get the complete analysis for PEJMF

EBITDA per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.39
Price
$2.57
GF Value